PARP inhibitors in prostate cancers, is it time for combinations?

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Metastatic prostate cancer remains a significant cause of cancer-related death.
• Homologous recombination repair (HRR) pathway alterations are linked to aggressive disease.
• PARP inhibitors (PARPi) like olaparib and rucaparib are approved for HRR-deficient metastatic castration-resistant prostate cancer (mCRPC), particularly with BRCA2 alterations.

Purpose of the Study:

• To review the advantages and disadvantages of PARPi as monotherapy in prostate cancer.
• To discuss the potential synergistic effects of combining PARPi with new hormonal therapies (NHTs).
• To evaluate the necessity of molecular selection for PARPi treatment, independent of HRR deficiency.

Main Methods:

• Literature review of existing studies on PARP inhibitors and new hormonal therapies in prostate cancer.
• Analysis of clinical trial data and research findings regarding PARPi efficacy.
• Exploration of emerging hypotheses on the combined use of PARPi and NHTs.

Main Results:

• PARPi demonstrate anti-tumoral effects in mCRPC patients with HRR gene alterations.
• Emerging evidence suggests potential synergistic activity between PARPi and NHTs.
• The efficacy of PARPi may extend beyond patients with HRR deficiencies.

Conclusions:

• PARPi represent a valuable therapeutic option for metastatic prostate cancer, especially in HRR-altered cases.
• Combining PARPi with NHTs may offer enhanced efficacy, potentially independent of HRR status.
• Further research is needed to define optimal treatment strategies and patient selection criteria for PARPi-based therapies.